Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Melatonin for COVID-19: real-time meta analysis of 18 studies
Covid Analysis, December 2022
https://c19early.org/jmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lissoni 91% 0.09 [0.01-1.57] 20mg hosp. 0/30 5/30 CT​1 Improvement, RR [CI] Dose (1d) Treatment Control Alizadeh (SB RCT) 73% 0.27 [0.07-1.05] 6mg no recov. 2/14 9/17 Ramlall (ICU) 87% 0.13 [0.08-0.22] n/a death 196 (n) 752 (n) Intubated patients Darban (RCT) 33% 0.67 [0.14-3.17] 24mg progression 2/10 3/10 ICU patients CT​1 Darban (RCT) 6% 0.94 [0.84-1.06] 24mg ICU 10 (n) 10 (n) ICU patients CT​1 Hosseini 48% 0.52 [0.36-0.77] 9mg recov. time 20 (n) 20 (n) Farnoosh (DB RCT) 81% 0.19 [0.01-3.65] 9mg ICU 0/24 2/20 Farnoosh (DB RCT) 49% 0.51 [0.32-0.81] 9mg recov. time 24 (n) 20 (n) Farnoosh (DB RCT) 44% 0.56 [0.10-3.00] 9mg no disch. 2/24 3/20 Farnoosh (DB RCT) 43% 0.57 [0.35-0.92] 9mg no disch. 24 (n) 20 (n) Sánchez-González 54% 0.46 [0.28-0.71] varies death 24/224 53/224 Mousavi (RCT) 67% 0.33 [0.04-3.09] 3mg death 1/48 3/48 Mousavi (RCT) 40% 0.60 [0.24-1.52] 3mg ICU 6/48 10/48 Hasan (RCT) 93% 0.07 [0.01-0.53] 10mg death 1/82 13/76 Bologna 50% 0.50 [0.13-1.86] 2mg death 3/40 6/40 Bologna 50% 0.50 [0.13-1.86] 2mg ICU 3/40 6/40 Bologna 9% 0.91 [0.83-1.00] 2mg hosp. time 40 (n) 40 (n) Bologna 39% 0.61 [0.53-0.71] 2mg s-i time 40 (n) 40 (n) Bologna 58% 0.42 [0.33-0.52] 2mg NIV time 40 (n) 40 (n) Bologna 8% 0.92 [0.78-1.09] 2mg HFO time 40 (n) 40 (n) Bologna 18% 0.82 [0.74-0.90] 2mg sleep 40 (n) 40 (n) Bologna 33% 0.67 [0.54-0.82] 2mg delirium 40 (n) 40 (n) Sánchez-Rico 19% 0.81 [0.61-1.08] 2mg death Karimpour-.. (ICU) 39% 0.61 [0.21-1.76] 15mg death 5/12 13/19 ICU patients Karimpour-.. (ICU) 43% 0.57 [0.28-1.18] 15mg ventilation time 12 (n) 19 (n) ICU patients Karimpour-.. (ICU) 2% 0.98 [0.81-1.19] 15mg ICU 12 (n) 19 (n) ICU patients Alizadeh (DB RCT) 4% 0.96 [0.80-1.16] 21mg death 28/33 30/34 Intubated patients Alizadeh (DB RCT) 14% 0.86 [0.70-1.06] 21mg no recov. 26/33 31/34 Intubated patients Alizadeh (DB RCT) 27% 0.73 [0.51-1.05] 21mg ventilation time 33 (n) 34 (n) Intubated patients Fogleman (DB RCT) 17% 0.83 [0.55-1.25] recovery 32 (n) 34 (n) Ameri (RCT) 29% 0.71 [0.62-0.82] 10mg death 73/109 110/117 ICU patients Ameri (RCT) 28% 0.72 [0.58-0.90] 10mg ventilation 56/109 83/117 ICU patients Ameri (RCT) 25% 0.75 [0.63-0.89] 10mg no recov. 109 (n) 117 (n) ICU patients Ameri (RCT) 25% 0.75 [0.57-0.98] 10mg recov. time 109 (n) 117 (n) ICU patients Ameri (RCT) 29% 0.71 [0.53-0.96] 10mg hosp. time 109 (n) 117 (n) ICU patients Jehi 58% 0.42 [0.26-0.68] n/a cases 16/529 802/11,143 Jehi 100% 0.00 [0.00-2.68] n/a cases 0/18 290/2,005 Zhou (PSM) 21% 0.79 [0.65-0.94] n/a cases García-G.. (DB RCT) 7% 0.93 [0.06-14.7] 2mg symp. case 1/163 1/151 García-G.. (DB RCT) -108% 2.08 [0.66-6.63] 2mg cases 9/163 4/151 Melatonin COVID-19 outcomes c19early.org/j Dec 2022 1 CT: study uses combined treatment Favors melatonin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit